Drugs / Centhaquin
Centhaquin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02408731 | Oct 2014 → Apr 2015 | — | Pharmazz, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Centhaquin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02408731 ↗ |
| Known as | centhaquin citrate | “The investigators are conducting a phase I clinical study in humans to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of centhaquin citrate in normal...” NCT02408731 ↗ |
| Known as | PMZ-2010 | “Centhaquin (PMZ-2010) in very low doses reduced blood lactate levels, improved blood pressure, cardiac output, survival and proved to be a highly effective resuscitative agent.” NCT02408731 ↗ |
| Route | Intravenous | “administered to each subject under supervision of investigator as an intravenous infusion over one hour” NCT02408731 ↗ |